Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346902 · ClinicalTrials.gov registry record · Phase 2
Study of EB-001 in Facial Scar Reduction
A Phase 2 study, sponsored by Bonti.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03346902 is a Phase 2 study that has completed, run by Bonti. The registered enrollment target is 12 participants.
The verdict
NCT03346902, a Phase 2 study, has completed, sponsored by Bonti.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of EB-001 in improving wound healing and reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead area following a single treatment of EB-001 when injected into the muscles underlying the incision area.
Interventions
- DRUG 0.9% Sodium Chloride Injection
- DRUG EB-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2018-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03346902
The ClinicalTrials.gov registry entry for NCT03346902 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bonti, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.9% Sodium Chloride Injection is the first listed.
NCT03346902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03346902 about?
NCT03346902 is a clinical study titled "Study of EB-001 in Facial Scar Reduction". This study will evaluate the safety and efficacy of EB-001 in improving wound healing and reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead area following a single treatment of EB-001 when injected into the muscles underlying the incision area.
What is the current status of trial NCT03346902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-02-06. Estimated completion is 2018-10-08.
What interventions are being tested in trial NCT03346902?
The interventions under investigation include: 0.9% Sodium Chloride Injection (DRUG), EB-001 (DRUG).
Who is sponsoring clinical trial NCT03346902?
This trial is sponsored by Bonti, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.